Concepedia

Rubén Salanova

RS

5

Publications

292

Citations

5

H-Index

2009

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Alberta

Uppsala University

Aichi Cancer Center

Charité - Universitätsmedizin Berlin

Rubén Salanova is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pathology, and lung cancer.

Top concepts

MedicinePathologyOncologyLung CancerRadiation OncologyCancer Cell BiologyImmunologyEndocrinologyTumor BiologyCancer Research

Publications per year

2009–2021

5

Publications

5

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

Manfred Dietel, Rubén Salanova, Patrick Micke et al. · Lung Cancer · 2019 · 155 citations

Tumor Biology, Prognostic Biomarkers, Real-world Prevalence +10

Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours

Víctor Zamora, Ana Cabanne, Rubén Salanova et al. · Digestive and Liver Disease · 2009 · 71 citations

Somatostatin Receptors, Pathology, Endocrinology +2

A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma

Soledad Iseas, Mariano Golubicki, Juan Robbio et al. · Translational Oncology · 2021 · 25 citations · Full text

Pre-Existing Tumoral B Cell Infiltration and Impaired Genome Maintenance Correlate with Response to Chemoradiotherapy in Locally Advanced Rectal Cancer

Juan M. Sendoya, Soledad Iseas, Mariana Coraglio et al. · Cancers · 2020 · 23 citations · Full text

130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study

Manfred Dietel, Rubén Salanova, Patrick Micke et al. · Journal of Thoracic Oncology · 2018 · 18 citations

Real-world Prevalence, Pd-l1 Expression, Advanced Lung Disease +10

Rows per page

1–5 of 5